An a-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Iniguez E, Schocker NS, Subramaniam K, Portillo S, Montoya AL, Al-Salem WS, Torres CL, Rodriguez F, Moreira OC, Acosta-Serrano A, Michael K, Almeida IC, Maldonado RA. An a-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major. PLoS Negl Trop Dis. 2017 Oct; 11(10):e0006039.

View in: PubMed

subject areas

Animals
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Epitopes
Galactosides
Galactosyltransferases
Gene Expression Regulation, Enzymologic
Glycoproteins
Humans
Leishmania major
Leishmaniasis Vaccines
Leishmaniasis, Cutaneous
Mice
Mice, Knockout

authors with profiles

Igor C. Almeida
Rosa A. Maldonado
Katja Michael

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support